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ABSTRACT
Atrial fibrillation (AF) and atherosclerotic disease are independent risk factors for acute ischaemic stroke (AIS). The optimal 
biological marker which could allow differentiation between AF and non-AF AIS patients is still not available. 
Aim of the study. Aim of the present study was to investigate the role of pentosidine as a potential biological marker for AF in 
an AIS patient group. 
Materials and methods. Sixty-three acute ischaemic hemispheric stroke patients were recruited and divided into two groups 
according to the presumed underlying mechanism: with or without atrial rhythm disorders. Ten healthy volunteers were a re-
ference group for serum level of pentosidine. Carotid artery ultrasound was performed, and common carotid artery stiffness 
and intima-media thickness were measured. Serum levels of pentosidine and selected routine biochemical risk factors for 
atherosclerosis (cholesterol and its lipoprotein fractions, homocysteine) were examined.
Results. A higher serum level of pentosidine was observed in patients without atrial fibrillation (1,509 ± 485.13pmol/ml); a sta-
tistically significant difference was observed compared to the reference group (1,041.52 ± 411.17pmol/ml; p = 0.01), but not 
the AF patients (1,438.19 ± 495.97pmol/ml; p = 0.59). No significant difference in the non-AF group compared to the AF group 
for carotid intima-media thickness (IMT)/stiffness and pentosidine serum level was recorded.  
Conclusions and clinical implications. A higher serum level of pentosidine was observed in AIS patients without atrial fibril-
lation compared to the healthy volunteers. According to the results of the present study, no difference between these patients 
in the selected risk factors of atherosclerosis were observed.  Further studies are needed to identify a reliable marker of AF that 
would bring added value to the standard diagnostic workup after acute ischaemic stroke.
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Introduction
Atrial fibrillation (AF) and atherosclerotic disease are 
independent risk factors for acute ischaemic stroke (AIS) 
[1–3]. In 20–25% of AIS cases, no causative factor can be 
found in routine tests. There is a need for biomarkers that 
are capable of identifying them. In recent years, a number 
of trials have studied the potential biological markers 
of AF. Four groups can be differentiated: markers of in-
flammation (e.g. pentraxin-3, neutrophil-to-lymphocyte 
ratio); markers of fibrosis (e.g. galectin-3, TGF-b1, matrix 
metalloproteinase – 9, growth/differentiation factor – 15); 
markers of hormonal activity (e.g. N-terminal prohormone, 
fibroblast growth factor – 23); and others (e.g. circulating 
procoagulant microparticles, asymmetric dimethylarginine, 
microRNA) [4, 5]. 
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Atherosclerosis is characterised by intramural thickening 
of the sub-intima, and therefore, the carotid intima-media 
thickness (IMT) is now used as a marker of subclinical at-
herosclerosis [6–11]. A popular hypothesis is that oxidative 
stress promotes atherogenesis by accelerating glycation, and 
leads to the accumulation of advanced glycation end products 
(AGEs), which increase tissue stiffness and reduce elasticity 
[12–14]. Pentosidine is a well-characterised natural AGE that 
is used as a biomarker for AGE production. 
Finding an optimal, biological marker for AF would be of 
great importance for stroke patients. 
Aim of study 
The aim of the present study was to investigate the role 
of pentosidine as a potential biological marker for AF in an 
AIS patient group. 
Materials and methods
Over 27 months, 73 participants were recruited into the 
study by neurologists working in the Department of Neurol-
ogy. The study group included 63 patients with hemispheric 
AIS, all of whom were treated at the stroke unit, plus 10 healthy 
volunteers (reference group for serum level of pentosidine). 
Hemispheric stroke was diagnosed based on the hemispheric 
syndrome. Age-matched staff family members were enrolled 
as the healthy controls. The inclusion criteria to the study 
group were as follows: (1) a patient with AIS, who (2) was 
able to provide informed consent. The exclusion criteria were: 
(1) a diagnosis other than AIS responsible for the neurologi-
cal syndrome and (2) a refusal or inability to give informed 
consent. The 63 stroke patients were divided into two groups, 
according to the presumed underlying mechanism i.e. with 
and without atrial rhythm disorders. AF was diagnosed in 
22 patients (the AF group). Patients were allocated to this 
group if there was a history of AF or if AF was observed during 
24 hours of ECG monitoring (a standard test during hospitali-
sation). The 41 remaining stroke patients, who did not have 
heart rhythm disorders, were assigned to the non-AF group. 
Carotid artery ultrasound was performed using the MY-
LAB 70 platform, with linear array transducer LA 522. IMT 
was measured at the posterior wall of the right and left CCAs, 
10 mm from the carotid bifurcation. CCA-IMT was measured 
with Mylab 70 (Esaote) using the software-guided technique 
RF-Quality Intima Media Thickness (QIMT, Esaote). A region 
of interest was superimposed on the B-mode image. The mean 
of the IMT values was continuously calculated by the system 
and displayed on the left side of the image. The IMT values 
were expressed in micrometres. An example of the CCA-IMT 
measurement is shown in Figure 1. Common carotid artery 
stiffness was assessed using the Automatic Quality Arterial Stiff-
ness (QAS) calculation, measuring the modification of arterial 
diameter between systolic and diastolic phases. The distensibility 
coefficient (DC), compliance coefficient (CC; ratio between 
variations in arterial cross-sectional area and blood pressure), 
and pulse wave velocity [PWV — time taken for a pressure pulse 
to travel between two set points] kPA-1 were calculated. The α 
and b stiffness parameters were calculated as follows:
a = A x ln(ps/pd)/ΔA,
where A — diastolic area, ΔA — change of area in systole, 
ps — systolic pressure, pd — diastolic pressure); and
b = D x ln(ps/pd)/ΔD,
where D — diastolic diameter, ΔD — change of diameter in 
systole, ps — systolic pressure, pd — diastolic pressure [15, 16].
All measurements of carotid stiffness were performed in 
the supine position by the same experienced neurosonologist 
(M.L.), both on the right and left common carotid arteries. 
Figure 1.  Common carotid artery intima-media thickness measurement using software-guided RF-Quality Intima Media Thickness (QIMT, 
Easote)
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For each patient, the systolic and diastolic brachial pressure 
was specified.
Routine biochemical risk factors for atherosclerosis, inclu-
ding the blood serum level of cholesterol and its lipoprotein 
fractions (high- and low-density lipoprotein; HDL and LDL, 
respectively), homocysteine and pentosidine were examined. 
All serum-level parameters were measured using standard 
laboratory practices within 72 hours of the onset of ischaemic 
stroke. The serum level of pentosidine was measured using 
a Human Pentosidine ELISA Kit (CUSABIO, Wuhan, China).
Characteristics of the study population were recorded and 
compared using the Student’s t-test, Mann–Whitney U test, 
Kendall’s tau-b test and Pearson’s chi-squared test. All statisti-
cal analyses were performed using PAWS Statistic 18 (SPSS). 
P<0.05 was considered statistically significant. 
The local Ethical Committee approved the study.
Results
A total of 31 men and 32 women participated in the study: 
22 AF patients (six men and 16 women; mean age: 76.82 years; 
age range: 61 to 90), and 41 non-AF patients (25 men and 
16 women; mean age: 72.49 years; age range: 44 to 91).  Four 
men and six women were included in the reference group 
(mean age: 71.8 years; age range: 66 to 78). The characteristics 
of each group are set out in Table 1. 
A higher serum level of pentosidine was reported in the 
non-AF patients. A statistically significant difference compared 
to the reference group (p = 0.01), but not to the AF patients, 
was observed. 
Although the distribution of males and females differed 
across the AF and non-AF groups, no statistically significant 
difference between men and women, in terms of any of the me-
asured parameters, was observed within the groups. A higher 
serum level of triglycerides in men in the non-AF, compared 
to the AF, group was observed (p = 0.008), but this was not the 
case for women. In both the AF and non-AF patient groups, 
the level of HDL cholesterol was higher (p = 0.016) and the 
CRP was lower (p = 0.04) in women than in men (Tab. 2). 
No statistically significant difference in the non-AF group 
compared to the AF group for DC, CC, PWV, IMT, α and ß 
stiffness and pentosidine serum level was recorded. Total cho-
lesterol, triglycerides and LDL cholesterol serum levels tended 
to be higher in the non-AF group compared to the AF group, 
but a statistically significant difference between the two was 
recorded only for triglycerides (p = 0.034).
No correlation between DC, CC, PWV, α and ß stiffness 
and pentosidine serum level was noted. 
Ten out of 63 patients (16%) suffered with diabetes 
mellitus (four in the AF group). Forty-four out of 63 (70%) 
patients were diagnosed with arterial hypertension (13 in the 
AF group), and none with renal insufficiency. No statistically 
significant difference in pentosidine serum level between 
diabetes mellitus patients (mean: 1,601 ± 540 pmol/ml) and 
patients without such a diagnosis (mean: 1,462 ± 478 pmol/ml; 
p = 0.41) was recorded. No statistically significant difference 
in pentosidine serum level between patients with arterial 
hypertension (mean: 1,534 ± 488 pmol/ml) and patients 
without such a diagnosis (mean: 1,379 ± 475 pmol/ml; 
p = 0.22) was noted. 
There was no correlation between patient age and pen-
tosidine serum level in the group of 63 patients (p = 0.70, 
r = -0.5), or in the AF group (p = 0.81, r = 0.05), or in the 
non-AF group (p = 0.64, r = -0.07).
Discussion
The present study provides a comparison of pentosidine 
serum level in non-AF and AF AIS patients. Little is known 
about the relationship between AGEs and AIS. A high serum 
level of pentosidine has been previously shown to be indica-
tive of a poor prognosis 30 days after acute stroke and to be 
associated with branch atheromatous disease among small 
vessels occlusion [17, 18].  
According to the results of the present study, no difference 
in serum level of pentosidine in non-AF and AF patients was 
noted. A higher serum level of pentosidine was reported in the 
non-AF patients, but there was a statistically significant dif-
ference compared only to the relatively small reference group 
(p = 0.01). There was no significant difference in the level of 
pentosidine between AF and healthy controls, but this is likely 
to have been caused by the sample size. The point estimates 
and SD in AF and non-AF groups are very similar. The p value 
of 0.06 indicates a clear tendency. Recent studies have shown 
higher subcutaneous content of AGEs in patients with subclini-
cal atheromatous disease than in subjects without disease. No 
difference in serum level of pentosidine was reported between 
patients with and patients without generalised atheromatous 
disease [19]. Further studies are necessary to explore this for 
the AIS patients, and to establish reference values for serum 
level pentosidine in healthy controls.
The results of the present study showed no difference in 
carotid artery stiffness/IMT in AIS patients with and without 
AF. This confirms previous reports that increased IMT is 
associated with an increased stroke risk in AF patients [20]. 
Common carotid IMT, in the absence of cardiovascular risk 
factors, is strongly related to age [21]. In the present study, 
the age of patients in both groups was comparable. Increased 
carotid IMT is associated also with blood pressure variability, 
obesity and overweight [22, 23]. These factors were not ana-
lysed in our study and they could interfere with the results. 
Mean IMT has been shown to be significantly correlated with 
systemic atherosclerotic change and PWV to predict the onset 
of stroke in hypertensive patients [24]. That was not confirmed 
in the present study, but hypertension was not an exclusion 
criterion in our study and patients with hypertension were 
included both in the AF and the non-AF groups. No dif-
ference in carotid artery stiffness/IMT in AIS patients with 
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and without AF, as shown in the present study, supports the 
previous reports that higher carotid IMT and greater arterial 
stiffness are associated with higher AF incidence, and play 
a role in AF aetiopathogenesis [25]. 
Although several interesting and potentially important 
relationships have been established in the present study, it 
does face some limitations: a relatively small group of patients, 
an overrepresentation of non-AF stroke patients, an uneven 
sex distribution in groups, and the method of AF/non-AF 
group allocation. The exclusion criterion “refusal or inability 
to give informed consent” was responsible for the relatively 
low number of patients recruited to the study. All patients 
with aphasia and critical illness, who were unable to provide 
informed consent, were excluded from the study. Currently, 
only 1/6 cases of stroke is attributed to AF. This is the reason 
for the overrepresentation of non-AF stroke patients in our 
study. Patients were allocated to the AF group either if there 
was a history of AF or if AF was registered during 24 hours 
of ECG monitoring. The detection of AF depends on the time 
of ECG monitoring [26], and is five times higher in 30-day 
event-triggered recording than when conventional 24-hour 
monitoring is used. One method of AF screening is an ex-
ternal miniaturised recorder with an adhesive electrode. This 
method enables the detection of AF in 12.3% of patients with 
stroke of unknown source during four weeks of monitoring 
[27]. This  means that, potentially, in five patients from the 
presented non-AF group, AF would be revealed during four 
weeks of ECG monitoring. Implantable cardiac monitors may 
be recommended for some patients with AIS. Precise criteria 
for that procedure could enable the detection of AF in ap-
proximately 30% of patients [28].
Conclusions
Serum level of pentosidine was higher in non-AF patients, 
but it did not differentiate between AF and non-AF patients. 
Cholesterol/LDL and carotid IMT correlate in patients 
without atrial fibrillation.
There was no difference in risk factors of atherosclerosis 
in the AF group compared to the non-AF group.
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